Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1

Interventions

Temozolomide 12Vincristine 9Irinotecan 8Cyclophosphamide 8cabozantinib 6X-Rays 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Etoposide 5regorafenib 4fludarabine 4Radiotherapy 4Phantoms, Imaging 4Ifosfamide 4Doxorubicin 4Radiation 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2liposomal doxorubicin 2ivosidenib 2irinotecan sucrosofate 2etoposide phosphate 2abemaciclib 2Zoledronic Acid 2Topotecan 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × silmitasertib × 1 year × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡